ArticleACS medicinal chemistry letters2015
Molecular Property Design: Does Everyone Get It?
Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- The impact of reward scalarization and weight scheduling on optimization dynamics in multi-objective molecular design.Journal of cheminformatics · 2026Article
- PyMolGen: Database-Driven Molecular Generation of Drug-Like Compounds.Journal of chemical information and modeling · 2026Article
- Query Matters: How Selection Strategies Influence Active Learning in Drug Discovery.Journal of chemical information and modeling · 2026Article
- Evaluation of a New Methylimidazole-Containing Thiosemicarbazone as a CuChemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Article
- ACES-GNN: can graph neural network learn to explain activity cliffs?Digital discovery · 2025Article
- Discovery of Highly Potent BET Inhibitors based on a Tractable Tricyclic Scaffold.ACS medicinal chemistry letters · 2025Article
- TGF-M: Topology-augmented geometric features enhance molecular property prediction.PLoS computational biology · 2025Article
- The long road of drug development for endometriosis - Pains, gains, and hopes.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Pyrazolo-Pyrimidinones with Improved Solubility and Selective Inhibition of Adenylyl Cyclase Type 1 Activity for Treatment of Inflammatory Pain.Journal of medicinal chemistry · 2024Article
- Beware of extreme calculated lipophilicity when designing cyclic peptides.Nature chemical biology · 2024Article
- DrugSynthMC: An Atom-Based Generation of Drug-like Molecules with Monte Carlo Search.Journal of chemical information and modeling · 2024Article
- Design and synthesis of non-hydroxamate lipophilic inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR):RSC advances · 2024Article
- Structure-property Relationships Reported for the New Drugs Approved in 2023.Mini reviews in medicinal chemistry · 2024Review
- From waste to wonder: exploring the hypoglycemic and anti-oxidant properties of corn processing by-products.Frontiers in chemistry · 2024Article
- Design of the Global Health chemical diversity library v2 for screening against infectious diseases.PLoS neglected tropical diseases · 2023Article
- A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2023Article
- Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders.Journal of medicinal chemistry · 2023Article
- Chemistry-intuitive explanation of graph neural networks for molecular property prediction with substructure masking.Nature communications · 2023Article
- Discovery of pyrazolopyrrolidinones as potent, broad-spectrum inhibitors ofFrontiers in tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The principles of molecular property optimization in drug design have been understood for decades, yet much drug discovery activity today is conducted at the periphery of historical druglike property space. Lead optimization trajectories aimed at reducing physicochemical risk, assisted by ligand efficiency metrics, could help to reduce clinical attrition rates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.